Milada Sirova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Milada Sirova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
B. Říhová
1 shared publicationD. Plocová
Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
1 shared publicationDaniil Starenko
Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, Prague 142 00, Czech Republic
1 shared publicationJ. Strohalm
1 shared publicationJ. Šrogl
Institute of Microbiology, Academy of Sciences of the Czech Republic, Vídeňská 1083, 142 20 Prague 4, Czech Republic
1 shared publicationJirina Kovarova
Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, Prague 142 00, Czech Republic
1 shared publication
Latest Publications
- Open Access
- 19 January 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (2) , 1510-1524
Lopinavir Derivative as Potent P-gp Inhibitor Enables Delivery through HPMA Copolymer Conjugates and Overcoming Tumor Chemoresistance to Conventional Cytostatic Drugs
Tumor chemoresistance caused by P-glycoprotein (P-gp) expression in cancer cells remains a significant challenge in cancer chemotherapy. Herein, a novel P-gp-inhibiting lopinavir derivative (LD) was synthesized via esterification of protease inhibitor lopinavir with 5-methyl-4-oxohexanoic acid. LD proved to be a potent P-gp inhibitor with EC50 ∼ 1 μM, capable of considerable sensitization of P-gp-expressing cancer cells to conventional cytostatic drugs in vitro. The oxo functional group introduced in LD allowed its covalent linkage with the N-(2-hydroxypropyl)methacrylamide copolymer carrier via a pH-sensitive hydrazone bond (P-LD). Polymer conjugation enhanced the pharmacological properties of LD in vivo, increasing its half-life in the bloodstream, protecting it from metabolic degradation, and promoting its accumulation in tumors via the enhanced permeability and retention effect. P-LD exhibited P-gp-inhibitory activity and sensitized cells to polymer-bound cytostatic drugs in vitro. Importantly, P-LD remarkably improved the antitumor efficacy of a polymer-bound doxorubicin in two P-gp-expressing mouse tumor models without exhibiting any systemic toxicity.
- 19 January 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (2) , 1510-1524
Open AccessLopinavir Derivative as Potent P-gp Inhibitor Enables Delivery through HPMA Copolymer Conjugates and Overcoming Tumor Chemoresistance to Conventional Cytostatic Drugs
Tumor chemoresistance caused by P-glycoprotein (P-gp) expression in cancer cells remains a significant challenge in cancer chemotherapy. Herein, a novel P-gp-inhibiting lopinavir derivative (LD) was synthesized via esterification of protease inhibitor lopinavir with 5-methyl-4-oxohexanoic acid. LD proved to be a potent P-gp inhibitor with EC50 ∼ 1 μM, capable of considerable sensitization of P-gp-expressing cancer cells to conventional cytostatic drugs in vitro. The oxo functional group introduced in LD allowed its covalent linkage with the N-(2-hydroxypropyl)methacrylamide copolymer carrier via a pH-sensitive hydrazone bond (P-LD). Polymer conjugation enhanced the pharmacological properties of LD in vivo, increasing its half-life in the bloodstream, protecting it from metabolic degradation, and promoting its accumulation in tumors via the enhanced permeability and retention effect. P-LD exhibited P-gp-inhibitory activity and sensitized cells to polymer-bound cytostatic drugs in vitro. Importantly, P-LD remarkably improved the antitumor efficacy of a polymer-bound doxorubicin in two P-gp-expressing mouse tumor models without exhibiting any systemic toxicity.
- 1 January 2014
- Published by Elsevier
- p. 324-348
Assessing immunological properties of biomaterials for bone regeneration applications
- 1 January 2014
- Published by Elsevier
- p. 324-348
Assessing immunological properties of biomaterials for bone regeneration applications
- 1 July 1996
- Published by Elsevier in Journal of Controlled Release
- Vol. 40 (3) , 303-319
Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A
- 1 July 1996
- Published by Elsevier in Journal of Controlled Release
- Vol. 40 (3) , 303-319
Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A